A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects

Centocor, Inc.49 enrolled

Overview

The purpose of this study is to evaluate the pharmacokinetics of golimumab in Japanese and Caucasian Males.

This is a randomized (study medication assigned by chance), double-blind (both the physician and subject do not know the assigned study medication) study to assess the safety, tolerability, immune response, pharmacokinetics (what the body does to the drug), of golimumab (Simponi). The study population will consist of 24 healthy male Japanese subjects and 24 healthy male Caucasian subjects. Subjects will receive a single dose of either 200 mg or 400 mg golimumab or placebo. Subjects will be in the study for up to 16 weeks. Safety assessments will be performed throughout the study and include obtaining and evaluating laboratory tests, vital signs (eg, blood pressure), and the occurrence and severity of adverse events. A single dose of 200 mg or 400 mg golimumab, or placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Healthy Volunteers

Interventions

400 mg golimumab or placeboDRUG

Single dose of 400 mg subcutaneously

200 mg golimumab or placeboDRUG

Single dose of 200 mg subcutaneously

Eligibility

Sex: MALEMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Have no clinically relevant abnormalities * non-smoker or agree to smoke no more than 10 cigarettes or 2 cigars per day throughout the study * Japanese subjects born in Japan, outside of Japan for no more than 5 years, and have Japanese parents and maternal and paternal grandparents, determined by subject's verbal report * Japanese subjects must have a valid Japanese passport * Caucasian subjects must have Caucasian parents. Exclusion Criteria: * Have or had a history of clinically significant, severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease * Have any underlying physical or psychological medical condition * Be unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins.

Locations (1)

Unnamed facility

Cypress, California, United States

Outcomes

Primary Outcomes

Pharmacokinetics (study of what the body does to the drug) of golimumab in Japanese and Caucasian Male subjects

Time frame: Week 12 (Day 78)

Determine the immune response of golimumab in Japanese and Caucasian Male subjects

Time frame: Week 12 (Day 78)

Safety of golimumab in Japanese and Caucasian Male subjects

Time frame: Week 12 (Day 78)

Tolerability of golimumab in Japanese and Caucasian Male subjects

Time frame: Week 12 (Day 78)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.